Menu
PacPremier
Magic Hour
Montecito
SoCal Gas
Loading...
You are here:  Home  >  'Thousand Oaks'  -  Page 61
Latest

Our view: Allan Hancock College perfect for 4-year degree

By   /  Friday, March 10th, 2017  /  Editorials, Latest news, Opinion  /  Comments Off on Our view: Allan Hancock College perfect for 4-year degree

A bill making its way through the General Assembly holds out the promise of bringing a four-year degree to an area of the Tri-Counties often described as the state’s biggest “academic desert.” State Assemblywoman Jacqui Irwin, a Democrat from Thousand Oaks, has introduced AB 405, a measure that would create a pilot program for a Read More →

Read More →
Latest

Amgen declares $1.15 per share dividend

By   /  Tuesday, March 7th, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Amgen declares $1.15 per share dividend

The board of directors for Thousand Oaks biotechnology company Amgen declared a $1.15 per share dividend March 3 for the second quarter of 2017. The dividend will be paid on June 8 to all stockholders of record as of the close of business on May 17. The company has a market cap of $130.1 billion Read More →

Read More →
Latest

Requests for proposals overlook value of face-to-face communication

By   /  Friday, February 24th, 2017  /  Latest news, Op/Eds  /  Comments Off on Requests for proposals overlook value of face-to-face communication

I’ve been in business for more than 30 years and in that time I’ve hired quite a few people. But in all that time, not once, did I hire a person based strictly on their resume and certainly I’ve never hired anyone without having met them first. In every instance, I felt it was important, Read More →

Read More →
Latest

Genentech sues Amgen over biosimilar drug info

By   /  Monday, February 20th, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Genentech sues Amgen over biosimilar drug info

Roch AG subsidiary Genentech filed a lawsuit against Amgen claiming the Thousand Oaks-based company obstructed its investigation of whether the biosimilar Amgen is developing for Genentech’s cancer treatment Avastin violates the company’s patents, according to reports Feb. 20. Sales for Avastin, a treatment for lung, colon, ovarian and other types of cancer, reached $6.8 billion Read More →

Read More →
Latest

Mixed-use developments tapping into built-in demand

By   /  Friday, February 17th, 2017  /  Real Estate, Top Stories, Top Story  /  Comments Off on Mixed-use developments tapping into built-in demand

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen applies for FDA approval of Blincyto

By   /  Tuesday, February 14th, 2017  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Amgen applies for FDA approval of Blincyto

Thousand Oaks-based Amgen submitted an application for Blincyto to the U.S. Food and Drug Administration, the company announced on Feb. 14. Amgen aims to gain approval for Blincyto to treat Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The drug was previously granted breakthrough therapy designation and accelerated approval in December 2014. “Acute Read More →

Read More →
Latest

Thousand Oaks Boulevard mixed-use project gets green light

By   /  Tuesday, February 14th, 2017  /  Latest news, Real Estate  /  Comments Off on Thousand Oaks Boulevard mixed-use project gets green light

The Thousand Oaks Planning Commission voted 3-1 to move ahead with the specific plan’s first mixed-use project on Feb. 13. Thousand Oaks-based Daly Group aims to turn the former Lupe’s Mexican restaurant at 1710 Thousand Oaks Boulevard into a three-story project featuring 36 apartments and close to 5,000 square feet of commercial space. The apartments Read More →

Read More →